Combination Immunotherapy for Cancer Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1382

Special Issue Editor


E-Mail Website
Guest Editor
Proteomics and Metabolomics Facility, Moulder Center for Drug Discovery Research, Temple University, Philadelphia, PA 19140, USA
Interests: cancer immunotherapy; proteomics; metabolomics; diabetes; COPD; HIV

Special Issue Information

Dear Colleagues,

This Special Issue is dedicated to exploring the fascinating field of combination immunotherapy and its potential to revolutionize cancer treatment. In recent years, immunotherapy has emerged as an exciting approach in the fight against cancer, harnessing the power of the immune system to target and destroy cancer cells. However, single-agent immunotherapy has shown limitations in achieving complete and durable responses in all patients. That is where combination immunotherapy comes into play. By combining different immunotherapeutic agents, such as immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell transfer, researchers and clinicians aim to enhance the effectiveness of treatment and overcome resistance mechanisms. Original research work and review articles covering the aforementioned or any novel biologics-mediated cancer treatment or immunotherapy will be considered for this Special Issue.

Dr. Carlos Alberto Barrero
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • immune checkpoint inhibitor
  • cancer vaccine
  • novel cancer therapy
  • treatment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1119 KiB  
Article
Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations
by Marcus Rathbone, Conor O’Hagan, Helen Wong, Adeel Khan, Timothy Cook, Sarah Rose, Jonathan Heseltine and Carles Escriu
Cancers 2024, 16(7), 1249; https://doi.org/10.3390/cancers16071249 - 22 Mar 2024
Viewed by 1074
Abstract
Contrary to Pemetrexed-containing chemo-immunotherapy studies, Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel (ABCP) treatment has consistently shown clinical benefit in prospective studies in patients with lung cancer and actionable mutations, where intracranial metastases are common. Here, we aimed to describe the real-life population of patients [...] Read more.
Contrary to Pemetrexed-containing chemo-immunotherapy studies, Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel (ABCP) treatment has consistently shown clinical benefit in prospective studies in patients with lung cancer and actionable mutations, where intracranial metastases are common. Here, we aimed to describe the real-life population of patients fit to receive ABCP after targeted therapy and quantify its clinical effect in patients with brain metastases. Patients treated in Cheshire and Merseyside between 2019 and 2022 were identified. Data were collected retrospectively. A total of 34 patients with actionable EGFR or ALK alterations had treatment with a median age of 59 years (range 32–77). The disease control rate was 100% in patients with PDL1 ≥ 1% (n = 10). In total, 19 patients (56%) had brain metastases before starting ABCP, 17 (50%) had untreated CNS disease, and 4 (22%) had PDL1 ≥ 1%. The median time to symptom improvement was 12.5 days (range 4–21 days), with 74% intracranial disease control rates and 89.5% synchronous intracranial (IC) and extracranial (EC) responses. IC median Progression Free Survival (mPFS) was 6.48 months, EC mPFS was 10.75 months, and median Overall Survival 11.47 months. ABCP in real-life patients with brain metastases (treated or untreated) was feasible and showed similar efficacy to that described in patients without actionable mutations treated with upfront chemo-immunotherapy. Full article
(This article belongs to the Special Issue Combination Immunotherapy for Cancer Treatment)
Show Figures

Figure 1

Back to TopTop